Stockreport

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in T...

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothel [Read more]